Home
World Journal of Advanced Research and Reviews
International Journal with High Impact Factor for fast publication of Research and Review articles

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

eISSN: 2581-9615 || CODEN: WJARAI || Impact Factor 8.2 ||  CrossRef DOI

Research and review articles are invited for publication in March 2026 (Volume 29, Issue 3) Submit manuscript

Ethnomedicine claim directed in-silico prediction of epidermal growth factor receptor kinase antagonist: an untapped reservoir of prospective anticancer agents

Breadcrumb

  • Home
  • Ethnomedicine claim directed in-silico prediction of epidermal growth factor receptor kinase antagonist: an untapped reservoir of prospective anticancer agents

Tope Abraham Ibisanmi 1, * Ayodele Ifeoluwa Faleti ², Peace Ifeoma Odjegba ¹, Olamide Joshua Babatunde ¹, Titiladunayo Samuel Oluwatoyin ¹, Olabanji Bukola Olayinka ¹, Alaba Adebola Abosede ¹ and Akinlolu Oluwatoyin Felicia ¹

1 Department of Microbiology, School of Life Sciences, Federal University of Technology Akure, P.M.B. 704, Akure Nigeria.
2 Department of Chemistry, School of Life Sciences, Federal University of Technology Akure, P.M.B. 704, Akure Nigeria.
 
Research Article
World Journal of Advanced Research and Reviews, 2023, 17(01), 662-669
Article DOI: 10.30574/wjarr.2023.17.1.0088
DOI url: https://doi.org/10.30574/wjarr.2023.17.1.0088
 
Received on 04 December 2022; revised on 19 January 2023; accepted on 22 January 2023
 
The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) that belongs to the ErbB family and governs important cellular functions like reproduction, survival, motility, and differentiation. Overexpression, intensification, and alteration of EGFR occur in a wide range of human malignancies and are associated with tumor progression and decreased anticancer drug sensitivity. As a result, EGFR has been identified as one of the primary anticancer targets. As cancer is more likely to be poorly understood in traditional medical practices, the extrapolation of an ethnomedicine-led strategy to identifying and prioritizing anticancer medicinal plants has been questioned. Nonetheless, given the challenges of developing innovative anticancer drugs that are effective, safe, inexpensive, and widely available, ethnomedicinal studies play critical roles in identifying relevant medicinal plants that can be further investigated. This study employed pharmacophore modeling, molecular docking, and molecular dynamics simulation to develop an effective agent as an inhibitor for EGFR. The final findings revealed that the selected bioactive compound stabilized the EGFR protein. The optimum orientations of the various inhibitors was Friedelin and it was chosen and subjected, along with the FDA-approved drug, to molecular dynamics modeling to determine the molecular interaction of the medication with various mutational sites in order to deduce the suitable orientation for the inhibitors. The study also attest to the ethnomedicinal claims that ethnomedicinal plants played a huge role in anticancer drug discovery and that their exploration can change the bleak picture cancer paints in our societies today.
 
Epidermal growth factor receptor; Ethnomedicinal plants; Cancer; Bioactive compound
 
https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2023-0088.pdf

Preview Article PDF

Tope Abraham Ibisanmi, Ayodele Ifeoluwa Faleti, Peace Ifeoma Odjegba, Olamide Joshua Babatunde, Titiladunayo Samuel Oluwatoyin, Olabanji Bukola Olayinka, Alaba Adebola Abosede and Akinlolu Oluwatoyin Felicia. Ethnomedicine claim directed in-silico prediction of epidermal growth factor receptor kinase antagonist: an untapped reservoir of prospective anticancer agents. World Journal of Advanced Research and Reviews, 2023, 17(1), 662-669. Article DOI: https://doi.org/10.30574/wjarr.2023.17.1.0088

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 World Journal of Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution